Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression

Chia Ming Chang, Soichiro Sato, Changsu Han

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD.

Original languageEnglish
JournalCNS Drugs
Volume27
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Treatment-Resistant Depressive Disorder
Antipsychotic Agents
Pharmacology
Depression
Buspirone
Pindolol
Methylphenidate
Tricyclic Antidepressive Agents
Major Depressive Disorder
Serotonin Uptake Inhibitors
United States Food and Drug Administration
Thyroid Hormones
Lithium
Folic Acid
MEDLINE
Antidepressive Agents
Meta-Analysis
Randomized Controlled Trials
Therapeutics
modafinil

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. / Chang, Chia Ming; Sato, Soichiro; Han, Changsu.

In: CNS Drugs, Vol. 27, No. SUPPL.1, 01.05.2013.

Research output: Contribution to journalReview article

@article{8e64505d185e4c7f8221321998d9f0a6,
title = "Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression",
abstract = "Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD.",
author = "Chang, {Chia Ming} and Soichiro Sato and Changsu Han",
year = "2013",
month = "5",
day = "1",
doi = "10.1007/s40263-012-0030-1",
language = "English",
volume = "27",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "SUPPL.1",

}

TY - JOUR

T1 - Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression

AU - Chang, Chia Ming

AU - Sato, Soichiro

AU - Han, Changsu

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD.

AB - Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD.

UR - http://www.scopus.com/inward/record.url?scp=84886281128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886281128&partnerID=8YFLogxK

U2 - 10.1007/s40263-012-0030-1

DO - 10.1007/s40263-012-0030-1

M3 - Review article

VL - 27

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - SUPPL.1

ER -